Elderly Patients Who Stop Antipsychotics Have Better Outcomes
Older adults are often prescribed antipsychotics off-label for behavioral control in the hospital. But there’s no evidence for antipsychotics helping, and a great deal of evidence of harm.
Researchers: “We Do Not Suggest” Antipsychotics for Depression
Augmenting with antipsychotics was no better at reducing suicide than adding antidepressants, but led to increased risk of death from other causes.
Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.
A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.
Exploding Myths About Schizophrenia: An Interview with Courtenay Harding
The Vermont Longitudinal Study, led by Courtenay Harding, belied conventional beliefs about schizophrenia by showing remarkably good outcomes for patients discharged in the 1950s and '60s.
Antipsychotics Increase Risk of Dementia; New Research Illuminates Why
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.
Do Antipsychotics Protect Against Early Death? A Review of the Evidence
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.
Deadly Prescriptions: New Study Links Antipsychotics to Life-Threatening Risks in Dementia Patients
With pharmaceutical companies pushing antipsychotics for off-label use, dementia patients are being put at risk for devastating health consequences. Research suggests safer alternatives exist—but why aren’t they being prioritized?
Contribution of Antipsychotics to Suicidality and Depression
Peter Lehmann reviews the contribution of antipsychotics to suicide and depression in schizophrenia in the current International Journal of Psychotherapy. Publications about the intrinsic effects of...
An FDA Whistleblower’s Documents: Commerce, Corruption, and Death
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
Largest Survey of Antipsychotic Experiences Reveals Negative Results
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.
Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia
A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.
The Charade of New Drug Approvals for Schizophrenia
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.
Long-term Outcomes Better for Those Who Stop Taking Antipsychotics
Research undermines the prolonged use of antipsychotics in schizophrenia treatment, suggesting improved social functioning and quality of life with discontinuation.
The BBC, Harrow, and a Public Left in the Dark
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.
Service-Users See Long-Term Antipsychotic Use as Compromising Recovery, Review Finds
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
The Case Against Antipsychotics
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
Wunderink: Antipsychotics Can Be Tapered Safely Without Increasing Relapse Risk
Tapering antipsychotics slowly and with supported decision-making may improve care for patients with psychosis.
Sudden Antipsychotic Withdrawal—Not Low Dose—Leads to Relapse
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.
Researchers Warn of “Brain Atrophy” in Children Prescribed Antipsychotics
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Very Slow Taper Best for Antipsychotic Discontinuation
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
Withdrawal from Antipsychotics
A review of the scientific literature related to the withdrawal of antipsychotics: animal studies, withdrawal symptoms, tapering success rates, and consumer accounts of discontinuation.
